Study of How Fasting Length and Temporary Pause of GLP-1 Medications Affect Stomach Food Remaining in Adults Using Liraglutide or Semaglutide

What this Trial Is About

Researchers are studying how the length of fasting and temporarily stopping certain diabetes medicines called Glucagon-Like-Peptide 1 GLP-1 receptor agonists affect the amount of food remaining in the stomach. The study focuses on people who use liraglutide injected, oral semaglutide, or injected semaglutide to understand differences in stomach emptying. Participants involvement length depends on which GLP-1 medication they are currently using. Participants will be assigned to receive one of three treatments liraglutide injected under the skin once daily, oral semaglutide taken once daily, or semaglutide injected once weekly. The study evaluates stomach emptying after fasting following either a solid high-fat meal or a liquid meal, with measurements taken at multiple times after fasting begins. The study lasts up to approximately 178 days depending on the medication group. During the study, participants will undergo assessments including gastric ultrasound to check stomach contents at several time points after fasting. Researchers will measure if the stomach is empty or contains solids, as well as the volume of gastric contents. These evaluations occur at specific visits over the study period. The goal is to better understand the effects of fasting duration and pausing medication on stomach emptying in people using these diabetes treatments.

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)